Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

127.36USD
4:00pm EDT
Change (% chg)

$-2.60 (-2.00%)
Prev Close
$129.96
Open
$129.52
Day's High
$129.93
Day's Low
$126.01
Volume
316,858
Avg. Vol
263,512
52-wk High
$173.18
52-wk Low
$108.50

JAZZ.OQ

Chart for JAZZ.OQ

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $7,866.75
Shares Outstanding(Mil.): 60.53
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 22.82 36.75 36.56
EPS (TTM): 5.69 -- --
ROI: 11.15 14.63 14.06
ROE: 22.69 15.43 14.98

BRIEF-Jazz Pharma Q2 adjusted earnings per share $2.63

* Jazz pharmaceuticals announces second quarter 2016 financial results

Aug 09 2016

BRIEF-Jazz Pharmaceuticals says majority of Celator's outstanding shares has been validly tendered

* Tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub

Jul 12 2016

BRIEF-Jazz Pharma presents data from study for treatment for excessive sleepiness

* Presents new data from a human abuse liability study for JZP-110, an investigational treatment for excessive sleepiness in patients with narcolepsy or with OBSTR

Jun 14 2016

BRIEF-S&P-Jazz Pharmaceuticals Plc ratings affirmed on Celator acquisition plan outlook stable

* Stable rating outlook reflects expectation that leverage will remain comfortably below 3x

May 31 2016

BRIEF-Jazz Pharma says termination fee for Celator deal is $45.8 mln

* If merger is terminated with respect to an unsolicited superior proposal, Celator to pay termination fee of $45.8 million - SEC filing Source text (http://1.usa.gov/1RIjjF1) Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 31 2016

Jazz Pharma to buy Celator in $1.5 billion deal

Ireland-based Jazz Pharmaceuticals Plc will buy U.S.-based Celator Pharmaceuticals Inc in a cash deal valued at about $1.5 billion, to gain access to an investigational product in development for treating acute myeloid leukemia.

May 31 2016

Jazz Pharma to buy Celator in $1.5 bln deal

May 31 Ireland-based Jazz Pharmaceuticals Plc will buy Celator Pharmaceuticals Inc in a deal valued at about $1.5 billion, to gain access to Celator's investigational product in development for treating acute myeloid leukemia.

May 31 2016

Jazz Pharma nears deal to buy Celator for about $1.5 billion - WSJ

Ireland-based Jazz Pharmaceuticals Plc is nearing a deal to buy Celator Pharmaceuticals Inc for about $1.5 billion, the Wall Street Journal reported.

May 30 2016

Jazz Pharma nears deal to buy Celator for about $1.5 bln -WSJ

May 30 Ireland-based Jazz Pharmaceuticals Plc is nearing a deal to buy Celator Pharmaceuticals Inc for about $1.5 billion, the Wall Street Journal reported.

May 30 2016

BRIEF-Jazz Pharmaceuticals Q1 gaap earnings per share $1.19

* Sees 2016 non-gaap adjusted net income per diluted share $11.10-$11.50

May 10 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.